GR MD 02

Drug Profile

GR MD 02

Alternative Names: Galactoarabino-rhamnogalaturonate

Latest Information Update: 21 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Galectin Therapeutics
  • Developer Galectin Therapeutics; Providence Cancer Center; Providence Health & Services
  • Class Antifibrotics; Antineoplastics; Antipsoriatics; Carbohydrates; Hepatoprotectants; Polysaccharides; Skin disorder therapies
  • Mechanism of Action Galectin 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Hepatic fibrosis; Liver cirrhosis; Plaque psoriasis
  • Phase I Head and neck cancer; Lung cancer; Malignant melanoma; Orofacial cancer
  • Preclinical Breast cancer; Diabetic nephropathies; Fibrosis; Prostate cancer; Pulmonary fibrosis; Renal fibrosis
  • Discontinued Non-alcoholic steatohepatitis

Most Recent Events

  • 25 Jan 2018 Galectin Therapeutics has patent protection for compositions of GR MR 02 (Combination therapy) for Cancer in Japan
  • 25 Jan 2018 Galectin Therapeutics has patent protection for GR MD 02 for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease in Japan
  • 25 Jan 2018 Galectin Therapeutics has patents for GR MD 02 for different indications in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top